Abilify takes 7 million Americans.
The US Food and Drug Administration has issued for the first time in history a marketing authorization for the drug, which is a tablet with a built-in microchip, writes the Financial Times.
The chip is embedded in the preparation of Abilify manufactured by the Japanese company Otsuka, which is used to treat various psychoses and is prescribed for schizophrenia. In the US, 7 million people take this medicine.
After swallowing the tablet, the chip will send information to the patient's mobile device and automatically forward it to the treating doctor. Due to this, it will be possible to avoid the situation when patients do not comply with the prescribed mode of medication, which is one of the most urgent problems of modern medicine, especially in the treatment of chronic diseases.
It is alleged that tablets with microchips will be administered only with the consent of patients.
According to the head of Otsuka in North America, Kabir Nath, innovative pills will be produced in limited quantities to determine demand. At the same time, he could not specify how much the drug with the chip would be more expensive than the usual medicine.